Abstract
Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 17-22 |
| Number of pages | 6 |
| Journal | Annals of the New York Academy of Sciences |
| Volume | 1275 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2012 |
Keywords
- Clinical trial
- Evidence-based medicine
- Ocular myasthenia
- Steroids
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- History and Philosophy of Science
Fingerprint Dive into the research topics of 'Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial'. Together they form a unique fingerprint.
Cite this
Benatar, M., Sanders, D. B., Wolfe, G. I., McDermott, M. P., & Tawil, R. (2012). Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. Annals of the New York Academy of Sciences, 1275(1), 17-22. https://doi.org/10.1111/j.1749-6632.2012.06780.x